Treatment of hereditary angioneurotic oedema (HANE) with tibolone.
OBJECTIVE
Eight women, aged 25-58 years, with hereditary angioneurotic oedema (HANE) were treated with tibolone, a synthetic steroid exhibiting oestrogenic, androgenic and progestational activity.


METHODS
Pilot study.


RESULTS
Tibolone at a dose of 2.5-7.5 mg/day significantly reduced the number and severity of attacks and the number of ampoules of C1-esterase inhibitor (C1-INH) needed for symptomatic therapy. The efficacy of tibolone was comparable to that of danazol, while the androgenic side-effects were considerably reduced.


CONCLUSIONS
Tibolone may represent an alternative to danazol administration for the prophylaxis of HANE in women.
Ott
H W
HW
Clinical Division of Gynaecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Austria. helmut.ott@uibk.ac.at
Mattle
V
V
Hadziomerovic
D
D
Licht
P
P
Döinghaus
K
K
Rubbert
A
A
Manger
K
K
Manger
B
B
Kalden
J
J
Wildt
L
L
D000328:Adult; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics*; D003174:Complement C1 Inactivator Proteins / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D010865:Pilot Projects; D016896:Treatment Outcome
D003174:Complement C1 Inactivator Proteins; D009652:Norpregnenes; C027385:tibolone